Search

Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.

Background Reversible bronchial obstruction characterizes asthma. Spirometry is the gold standard to assess airflow, and FEV1 is the most reliable parameter in this regard. However, many children with asthma have FEV1 within the normal range despite uncontrolled asthma and worsening. Therefore, FEF25-75 has been proposed as a valuable marker of early airflow impairment. This study aimed at investigating FEF25-75 in a cohort of children with newly diagnosed asthma. Methods 381 children (122 females, mean age 11.6 years) were consecutively visited and had a new asthma diagnosis. In addition, Spirometry, type-2 phenotyping, asthma control assessment, and ACT were performed. Results 72 (18.9%) asthmatic children had impaired FEF25-75, such as <65% of predicted. Low FEF25-75 was associated with lower FVC and FEV1/FVC values (OR 1.11 and 1.32, respectively). Children with normal FEV1 but impaired FEF25-75 had more frequently uncontrolled asthma (15.8% vs. 32.4%) than children with both parameters within the normal range. Conclusions FEF25-75 deserves adequate and careful consideration in children with asthma, and the presence of impaired FEF25-75 values suggests a more compelling approach.

Allergic respiratory diseases, such as asthma and allergic rhinitis, are global health issues and have had an increasing prevalence in the last decades. Allergen-specific immunotherapy (AIT) is the only curative treatment for allergic rhinitis and asthma, as it has a disease-modifying effect. AIT is generally administered by two routes: subcutaneous (SCIT) and sublingual immunotherapy (SLIT). Local side effects are common, but usually well-tolerated and self-limited. However, systemic side effects are rare, and associated with uncontrolled asthma and bronchial obstruction, or related to errors in administration. Physicians should constantly assess potential risk factors for not only reporting systemic reactions and fatalities but also implementing other therapies to improve AIT safety. This paper highlights recent evidence on local and systemic reactions related to SCIT and SLIT in children., (© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

To date, the only disease-modifying treatment strategy for allergic rhinitis and asthma is allergen immunotherapy (AIT). There is evidence that AIT improves allergic rhinitis and asthma, such as reducing symptom severity and medication use and improving of quality of life, with a long-lasting effect after the end of the course. The recent clinical trials evidenced AIT effectiveness and safety in allergic asthma. Consequently, the current version of the GINA (Global Initiative for Asthma) guidelines recommend AIT as an add-on therapy for asthma. There is also evidence that AIT may exert preventive activity on the possible progression from allergic rhinitis to asthma in children and the onset of new sensitizations.

The control of asthma is the objective of asthma management. However, it is difficult to obtain in clinical practice. The Italian Society of Allergy and Clinical Immunology promoted the nationwide project "ControL'Asma" to investigate the real situation in a group of children and adolescents with asthma. The preliminary outcomes demonstrated that many asthmatic subjects do not achieve adequate asthma control. Moreover, asthma in Italian children and adolescents was usually more frequent in males, had an early onset and allergic phenotype with very frequent rhinitis comorbidity, uncontrolled and partly controlled asthma affected about the half of subjects. However, this project suggested that the assessment of asthma symptom perception by VAS could be a reliable tool in the asthma management.

Allergen immunotherapy (AIT) represents at present the unique disease-modifying treatment strategy for IgE-mediated allergic diseases. AIT can induce clinical improvement of allergic asthma, including reduced symptoms, medication use, and improvement of quality of life, with a long-lasting effect after cessation of treatment. Notably, the current asthma guidelines are now recommending sublingual immunotherapy as an add-on therapy for asthma in adults and adolescents with house dust mite allergy. Clinical indications of AIT, with particular reference to pediatric asthma, mechanisms of clinical and immunological tolerance to allergens, and the potential biomarkers predicting clinical response are discussed., (© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Background: In children with asthma, discrepancies between objective indicators of airway obstruction and symptom perception are often observed. Although visual analogue scale (VAS) has been proposed as a useful tool for assessing accurate symptom perception, previous studies conducted in children with asthma included only small cohorts. A study was therefore designed to investigate the usefulness of VAS in establishing a reliable relationship between breathlessness perception and lung function in a large cohort of children with clinical diagnosis of asthma., Methods: A total of 703 children [470 boys and 233 girls, median age 10.29 (8.33-12.58) yr] with asthma were included in this cross-sectional, real-life study. Perception of breathlessness was assessed by using VAS, and lung volumes and expiratory flows were measured by spirometry., Results: Most children had intermittent or mild persistent asthma (93.3%), and only 46 children had a significant bronchial obstruction defined by FEV(1) values <80% of predicted. Globally, VAS was significantly, even though weakly, related to lung function. Analyzing children with bronchial obstruction, a moderate relationship between both FEV(1) (r = 0.47) and FEF(25-75) (r = 0.42) and VAS was detected. A VAS value of 6 was found to be a reliable cutoff for discriminating children with bronchial obstruction (AUC 0.83 at ROC curve; OR 9.4)., Conclusion: The present study demonstrates that VAS might be considered a useful tool to assess symptom perception, mainly in children with airflow limitation., (© 2012 John Wiley & Sons A/S.)

Background: Studies on the role of cat ownership in the development of allergy have lead to conflicting results, probably owing to heterogeneity of the populations evaluated., Objective: To evaluate the possible effect of cat ownership on the frequency of sensitization and asthma or rhinitis in children living in Liguria, Italy, who attended a pediatric clinic for respiratory symptoms., Methods: We enrolled 269 consecutive school-aged children in 12 months. Sensitization to aeroallergens by skin prick testing and the presence of respiratory symptoms (ie, asthma and rhinitis) were evaluated. To analyze the role of different independent variables in association with respiratory symptoms and sensitization, a multiple logistic regression analysis was performed., Results: Of 269 children, 81 were exposed to cats at home in the first 2 years of life ("early" cat owners), 65 after the first 2 years of life ("late" cat owners), and 123 never ("never" cat owners). Early cat ownership was significantly associated with a lower risk of cat sensitization compared with never cat ownership (adjusted odds ratio [ORadj], 0.32; 95% confidence interval [CI], 0.14-0.74; P = .01). Early cat ownership was also associated with a significantly lower risk of allergic rhinitis than late cat ownership (ORadj, 0.43; 95% CI, 0.22-0.85) or never cat ownership (ORadj, 0.51; 95% CI, 0.28-0.92). No differences in the frequency of asthma were found among the 3 groups (P = .74), Conclusions: Cat ownership in early childhood can play an important role in preventing sensitization to cat and in lowering the frequency of allergic rhinitis, at least in children with the characteristics of the population studied.

Allergy is an important risk factor for asthma in children as most of asthmatic children are sensitized. The aim of the study was to investigate the natural course of sensitizations in a group of children (340) at the onset of asthmatic symptoms. We subdivided children in three groups depending on the age at first visit (3-7-11 years) and followed them for 4 years. All children underwent three visits, each including skin prick test, every two years. In the 3-year age group (n = 133), 59% of children were sensitized at first visit, but the percentage increase to 88% at third visit. When looking only at allergic children at first visit (261), we demonstrated that polysensitization became higher than monosensitization since the age of 11. Analysis of sensitization distribution over the time revealed that house dust mites were prominent from the age of 3 years. Parietaria and grass pollens as well as olive pollen significantly increased, particularly during the 4-year follow-up in the 7-year group. Analysis of sensitization score demonstrated that the age range from 3 to 11 is at high risk to polysensitization. In conclusion, this study provides evidence that sensitization is frequent in asthmatic children, polysensitization represents the natural history of allergy and the type of immune response should appear different for each allergen.

Objective: Allergic rhinitis and asthma share an immunoglobulin E-mediated inflammatory reaction following exposure to the causal allergen. Asthma control is associated with rhinitis control. Glycyrrhetic acid is extracted from the licorice and has an anti-inflammatory property. Mannitol is an anti-edema molecule. A medical device contains these components. This study evaluated the medical device efficacy on symptoms and asthma control in children with allergic rhinitis and mild controlled asthma. Methods: The children took 2 puffs of the medical device for each nostril twice a day for 4 weeks. Symptom severity was evaluated considering the total symptom score and nasal obstruction. Symptom perception was assessed by children and doctors using the visual analog scale. Asthma severity and control were also evaluated. Parents judged the efficacy. Results: The study included 38 children: 18 (47.4%) females and 20 (52.6%) males; the mean age was 10.2 (±2.15) years. The treatment significantly reduced the severity of all symptoms, including nasal obstruction (P < .001). Both children and doctors perceived a reduction of symptom intensity (P < .001). Parents judged the treatment as effective. Asthma remained mild and controlled. Conclusions: This pilot study, conducted in clinical practice, showed that intranasal glycyrrhetic acid plus mannitol could reduce nasal symptoms, including obstruction, and maintain asthma control. Therefore, this multicomponent medical device could represent a potential option in children with allergic rhinitis and mild controlled asthma. [ABSTRACT FROM AUTHOR]

Previously, evidence has been provided that sensitization is frequent in asthmatic children and polysensitization represents the natural history of allergy. The aim of this study was to investigate whether polysensitization may occur primarily in infants with wheezing. Thus, 98 infants (<1 year of age) were studied at the onset of wheezing symptoms. All children underwent three visits (each including skin-prick test): at baseline and after 2 and 5 years. At onset of wheezing, &thksim;20% of infants were sensitized, whereas at 6 years the percentage was >60%. The most important finding was that there was no polysensitized infant at baseline, whereas most of the sensitized children were polysensitized at 6 years. Moreover, the number of sensitizations increased with age. House-dust mites were the most important cause of allergic symptoms. Wheezing may disappear mainly in nonallergic children. In conclusion, this study provided the first evidence that respiratory allergy always starts with monosensitization and confirms previous studies concerning the natural history of allergy characterized by the progression toward polysensitization. [ABSTRACT FROM AUTHOR]